Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Updates on Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
share announcement

Updates on Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".

Deadline for manuscript submissions: 30 June 2025 | Viewed by 1373

Special Issue Editors

Dr. Luca Marzi

E-Mail
Guest Editor
Gastroenterology Unit, Bolzano Regional Hospital, 39100 Bolzano, Italy
Interests: hepatocellular carcinoma; liver tumors; diagnosis; treatment; viral liver infections; acute or chronic liver failure
Dr. Rodolfo Sacco

E-Mail Website
Guest Editor
Department of Surgical and Medical Sciences, University of Foggia, 71100 Foggia, Italy
Interests: hepatocellular carcinoma; liver tumors; diagnosis; treatment; inflammatory bowel disease

Special Issue Information

Dear Colleagues,

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. In recent years, the management of patients with HCC has changed considerably, due to improvements in molecular biology knowledge and the introduction of immunotherapy. To date, systemic therapy is authorized in patients with advanced HCC.

Moreover, there is increasing evidence that immunotherapy could also play a role as an adjuvant therapy in intermediate stages, pre-transplant downstaging, or post-liver-transplant recurrence.

Despite improvements over the years, these indications are not fully endorsed or stated in the guidelines due to the absence of studies and trials.

This Special Issue aims to explore the field of immunotherapy in liver cancer, evaluating innovative aspects and developing those that are poorly defined or already addressed. A first objective will be to gather evidence on the potential role of immunotherapy in all stages, not just the advanced stage.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following: the role of immunotherapy in all stages of liver cancer and in combination with other treatment techniques. In addition, interesting data may concern the effect of immunotherapy on the tumor microenvironment.

We look forward to receiving insightful contributions.

Dr. Luca Marzi
Dr. Rodolfo Sacco
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatocellular carcinoma
  • immunotherapy
  • immuno-oncology
  • immune checkpoint inhibitors
  • clinical trial
  • immunological microenvironments

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

10 pages, 830 KiB  
Article
A Proposal for a Simple Subclassification of Advanced Hepatocellular Carcinoma in Systemic Treatment
by Norihiro Imai, Takafumi Yamamoto, Kazuyuki Mizuno, Shinya Yokoyama, Kenta Yamamoto, Takanori Ito, Yoji Ishizu, Teiji Kuzuya, Takashi Honda, Tetsuya Ishikawa and Hiroki Kawashima
Cancers 2024, 16(22), 3797; https://doi.org/10.3390/cancers16223797 - 12 Nov 2024
Viewed by 1042
Abstract
Objectives: This study focused on the presence or absence of vascular invasion and extrahepatic metastasis in hepatocellular carcinoma (HCC) and examined their impact on systemic treatment outcomes. Methods: We retrospectively analyzed 362 patients with unresectable HCC who received first-line systemic therapy. The prognostic [...] Read more.
Objectives: This study focused on the presence or absence of vascular invasion and extrahepatic metastasis in hepatocellular carcinoma (HCC) and examined their impact on systemic treatment outcomes. Methods: We retrospectively analyzed 362 patients with unresectable HCC who received first-line systemic therapy. The prognostic evaluation was based on the presence of vascular invasion and extrahepatic metastasis at the time of treatment initiation. Results: Patients with vascular invasion or extrahepatic metastasis (advanced group) had significantly worse outcomes than those without these features (intermediate group), with median survival times of 434 and 658 days, respectively. Further subdivision of the advanced group into three categories—patients with only extrahepatic metastasis (m group, n = 77), patients with only vascular invasion (v group, n = 78), and patients with both vascular invasion and extrahepatic metastasis (vm group, n = 52)—revealed that the m group had significantly better outcomes than those in the other two groups, with median survival times of 649, 323, and 187 days, respectively. A comparison of the clinical backgrounds among the three groups demonstrated that the m group had significantly better liver function at the time of treatment initiation than that in the other two groups. Multivariable analysis, including performance status, Child–Pugh score, and the use of immune checkpoint inhibitors as first-line therapy, identified the m group as an independent and significant prognostic factor (hazard ratio, 0.50). Conclusions: Unresectable HCC with extrahepatic metastasis and no vascular invasion represents a novel staging category for systemic treatment. Full article
(This article belongs to the Special Issue Updates on Immune Checkpoint Inhibitors in Hepatocellular Carcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop